Notch Inhibitor in Advanced Cancer

• Status: Completed
• Trial end date: 2012-08-01

Summary

The objective of this phase 1 study is to evaluate the safety and tolerability of Notch Inhibitor in participants with advanced cancer. This study includes dose escalation and dose confirmation components.

• Phase: Phase 1

Details

• Lead Sponsor: Eli Lilly and Company